000162299 001__ 162299
000162299 005__ 20251017144606.0
000162299 0247_ $$2doi$$a10.1038/s41541-025-01201-1
000162299 0248_ $$2sideral$$a144878
000162299 037__ $$aART-2025-144878
000162299 041__ $$aeng
000162299 100__ $$aMata, Elena
000162299 245__ $$aPreserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C
000162299 260__ $$c2025
000162299 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162299 5203_ $$amRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
000162299 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/DGA/B29-20R$$9info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087$$9info:eu-repo/grantAgreement/ES/ISCIII/COV20-00308
000162299 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000162299 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162299 700__ $$aBroset, Esther
000162299 700__ $$aMatute, Carlos
000162299 700__ $$aStoian, Andrei
000162299 700__ $$aAdame, Susana
000162299 700__ $$aAlejo, Teresa
000162299 700__ $$aLópez, Alexandre
000162299 700__ $$aAndrés, Beatriz
000162299 700__ $$aHeredero, Juan
000162299 700__ $$ade Miguel, Diego
000162299 700__ $$aGiménez-Warren, Javier
000162299 700__ $$aLampaya, Verónica
000162299 700__ $$aCasabona, Diego
000162299 700__ $$aCalvo, Alba
000162299 700__ $$aQuincoces, Gema
000162299 700__ $$aPeñuelas, Iván
000162299 700__ $$aGamazo, Carlos
000162299 700__ $$aUranga, Iratxe
000162299 700__ $$aPeña, Natacha
000162299 700__ $$0(orcid)0000-0002-9730-2210$$aArias, Maykel
000162299 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000162299 700__ $$0(orcid)0000-0001-6629-6842$$aMoreno, Bernardino$$uUniversidad de Zaragoza
000162299 700__ $$0(orcid)0000-0002-7173-7216$$aBadiola, Juan$$uUniversidad de Zaragoza
000162299 700__ $$0(orcid)0000-0002-8784-7735$$aMartínez-Oliván, Juan
000162299 700__ $$aPérez-Herrán, Esther
000162299 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000162299 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000162299 773__ $$g10, 135 (2025), 19$$pnpj Vaccines$$tnpj Vaccines$$x2059-0105
000162299 8564_ $$s2928116$$uhttps://zaguan.unizar.es/record/162299/files/texto_completo.pdf$$yVersión publicada
000162299 8564_ $$s2814186$$uhttps://zaguan.unizar.es/record/162299/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162299 909CO $$ooai:zaguan.unizar.es:162299$$particulos$$pdriver
000162299 951__ $$a2025-10-17-14:15:41
000162299 980__ $$aARTICLE